Inspire Medical Systems faces class action lawsuit over misleading statements
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 08 Dec 25
Source: Globenewswire
Inspire Medical Systems Inc saw a price increase of 5.03% as it crossed above the 5-day SMA amid ongoing market challenges.
The company is currently facing a class action lawsuit for allegedly making false statements regarding the launch of its Inspire V device, which has led to significant investor losses. The lawsuit highlights concerns about the company's transparency and governance, as investors were assured of strong demand that did not materialize.
As the lawsuit progresses, investor confidence may continue to fluctuate, impacting the stock's performance. The outcome could have substantial implications for the company's future, especially in light of the recent challenges surrounding the Inspire V launch.
Analyst Views on INSP
Wall Street analysts forecast INSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSP is 145.31 USD with a low forecast of 91.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
13 Buy
6 Hold
0 Sell
Moderate Buy
Current: 82.010
Low
91.00
Averages
145.31
High
180.00
Current: 82.010
Low
91.00
Averages
145.31
High
180.00
About INSP
Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. It has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
